David Curtin
David Curtin is the Vice President & General Manager of the Biologics Business at Waters Corporation.
David Curtin is the Vice President & General Manager of the Biologics Business at Waters Corporation.
The FDA’s October 29, 2025 draft guidance has generated significant attention due to the implications for both developers and patients. By allowing developers to bypass comparative efficacy studies (CES) when advanced analytics are successful substitutes, the draft guidance avoids one of the most expensive steps, estimated to account for 70% of the total biosimilar development…